Literature DB >> 22564137

Pharmacotherapy for breakthrough cancer pain.

Julian Howell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22564137     DOI： 10.2165/11631050-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  4 in total

Review 1.  Pharmacotherapy for breakthrough cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

2.  Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study.

Authors:  Bo Lennernäs; Ingela Frank-Lissbrant; Hans Lennernäs; Karl Mikael Kälkner; Rob Derrick; Julian Howell
Journal:  Palliat Med       Date:  2009-12-16       Impact factor: 4.762

3.  Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.

Authors:  Hans Georg Kress; Anna Orońska; Zbigniew Kaczmarek; Stein Kaasa; Torben Colberg; Thomas Nolte
Journal:  Clin Ther       Date:  2009-06       Impact factor: 3.393

4.  Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.

Authors:  Richard L Rauck; Marvin Tark; Eva Reyes; Teresa G Hayes; Anthony J Bartkowiak; David Hassman; Srinivas Nalamachu; Rob Derrick; Julian Howell
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.